We're very fortunate in this field to have an abundance or leaders who seem entirely motivated by advancing the field and helping others with their professional development. In my limited experience, more so than any other field of bio medial research. Few however were as patient and generous as Tom. Many in this group are probably aware of the story of how he came to have NONMEM license #1 and how he was one of the few who gained Stuart's trust and respect early in the history of PMX, and the critical role he played in bring these methods into mainstream pharmaceutical research, a testament to both his technical knowledge and leadership skills. Like many others I personally benefited from my interactions with him.
Mark Mark Sale M.D. Vice President Integrated Drug Development mark.s...@certara.com Remote-Forestville CA Office Hours 9 AM - 5 PM Eastern Time +1 302-516-1684 www.certara.com [Certara Logo] From: owner-nmus...@globomaxnm.com <owner-nmus...@globomaxnm.com> On Behalf Of Nick Holford Sent: Saturday, August 3, 2024 1:20 AM To: nmusers@globomaxnm.com Subject: RE: [NMusers] Sad news about Dr. Ludden CAUTION: This email originated from outside of Certara. Do not click links or open attachments unless you recognize the sender and know the content is safe. Thanks to nmusers for informing me of this sad news. I have known Tom for many years but we only occasionally met face to face. I echo the sentiments of others below who spoke of his depth of knowledge and gentleness. He helped me many times when I was struggling with NONMEM and I think we always found a solution. We wrote one publication together, a book chapter on the "Time Course of Drug Effect". This echoed what is my earliest citation of Tom's scientific contributions nearly 40 years age (Svec JM, Coleman RW, Mungall DR, Ludden TM. Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to warfarin therapy: preliminary evaluation. Ther Drug Monit. 1985;7(2):174-80.). Tom, I hope in your afterlife you will still be able to follow nmusers. Thank you for all you have given to so many of us. -- Nick Holford, Professor Emeritus Clinical Pharmacology, MBChB, FRACP mobile: NZ+64(21) 46 23 53 ; FR+33(6) 62 32 46 72 email: n.holf...@auckland.ac.nz<mailto:n.holf...@auckland.ac.nz> web: http://holford.fmhs.auckland.ac.nz/ From: owner-nmus...@globomaxnm.com<mailto:owner-nmus...@globomaxnm.com> <owner-nmus...@globomaxnm.com<mailto:owner-nmus...@globomaxnm.com>> On Behalf Of Patel, Bela Sent: Saturday, August 3, 2024 1:43 AM To: ENE ETTE <ene_e...@anoixiscorp.com<mailto:ene_e...@anoixiscorp.com>>; Diane Mould <drmo...@pri-home.net<mailto:drmo...@pri-home.net>>; Riley, Steve <steve.ri...@pfizer.com<mailto:steve.ri...@pfizer.com>>; nmusers@globomaxnm.com<mailto:nmusers@globomaxnm.com> Subject: RE: [External email][NMusers] Sad news about Dr. Ludden Some people who received this message don't often get email from bela.pa...@merck.com<mailto:bela.pa...@merck.com>. Learn why this is important<https://aka.ms/LearnAboutSenderIdentification> Public Dear All, I am extremely saddened to hear this news. As mentioned by Ene, Dr. Tom Ludden was one of the pioneers in advancing pharmacometrics along with Dr. Beal and Dr. Sheiner promoting its value and impact in drug discovery and development as well as acceptance by the FDA. He provided invaluable scientific advice and trained numerous scientists in pharmacometrics. He was a real gentle soul and it was truly a privilege to have known him and be tutored by him. May his soul rest in peace. Sincerely, Bela From: owner-nmus...@globomaxnm.com<mailto:owner-nmus...@globomaxnm.com> <owner-nmus...@globomaxnm.com<mailto:owner-nmus...@globomaxnm.com>> On Behalf Of ENE ETTE Sent: Friday, August 2, 2024 5:30 PM To: Diane Mould <drmo...@pri-home.net<mailto:drmo...@pri-home.net>>; Riley, Steve <steve.ri...@pfizer.com<mailto:steve.ri...@pfizer.com>>; nmusers@globomaxnm.com<mailto:nmusers@globomaxnm.com> Subject: RE: [External email][NMusers] Sad news about Dr. Ludden Some people who received this message don't often get email from ene_e...@anoixiscorp.com<mailto:ene_e...@anoixiscorp.com>. Learn why this is important<https://aka.ms/LearnAboutSenderIdentification> EXTERNAL EMAIL- Use caution with any links or file attachments. Dear All: In Dr. Ludden we lost an excellent scientist who helped to revolutionize and advance clinical pharmacokinetics, pharmacometrics, clinical pharmacology, and drug development. I'm indebted to him for the impact he made on my life as a pharmacometrician, clinical pharmacologist, and drug developer while working with him at the FDA. He started the Pharmacometrics Staff Unit which became Pharmacometrics Division in later years. May his soul rest in peace. Sincerely, Ene. Sent from Mail<https://go.microsoft.com/fwlink/?LinkId=550986> for Windows From: Diane Mould<mailto:drmo...@pri-home.net> Sent: Friday, August 2, 2024 4:03 PM To: Riley, Steve<mailto:steve.ri...@pfizer.com>; nmusers@globomaxnm.com<mailto:nmusers@globomaxnm.com> Subject: RE: [External email][NMusers] Sad news about Dr. Ludden Dear All I am very saddened to hear this news. Tom Ludden was one of the nicest and smartest people that I have ever known. He was a gentle giant in our field and I will miss him. Best Diane From: owner-nmus...@globomaxnm.com<mailto:owner-nmus...@globomaxnm.com> <owner-nmus...@globomaxnm.com<mailto:owner-nmus...@globomaxnm.com>> On Behalf Of Riley, Steve Sent: Friday, August 2, 2024 2:41 PM To: nmusers@globomaxnm.com<mailto:nmusers@globomaxnm.com> Subject: [External email][NMusers] Sad news about Dr. Ludden CAUTION: This email originated from outside the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe. Dear NM-Users, Regrettably, I am writing to let you know that Dr. Ludden passed away Tuesday evening, 30JUL2024. I was able to get there over the weekend prior to visit him and his family. During his wakeful moments we had some good scientific discussions. We talked a lot about NONMEM and how its functionality and utility has expanded since he retired. He was pleased to hear about the changes. He was surrounded by family for the days leading up to the end. They were all appreciative that I was able to get there and tell him (and them) how much he meant to all of us and the impact he had on our careers. I think memories of Dr. Ludden were characterized perfectly by Marc Gastonguay, "I am forever grateful for the positive impact that Tom had on my life and career, not to mention the tremendous, although often underappreciated, contributions he made to the disciplines of clinical pharmacology and pharmacometrics. His humble brilliance will be missed and fondly remembered." Steve Riley This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (126 East Lincoln Ave., P.O. Box 2000, Rahway, NJ USA 07065) and/or its affiliates, that may be confidential, proprietary copyrighted and/or legally privileged. (Direct contact information for affiliates is available at - Contact us - MSD<https://www.msd.com/contact-us/>.) It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system. This message (including any attachments) may contain confidential, proprietary, privileged and/or private information. The information is intended to be for the use of the individual or entity designated above. If you are not the intended recipient of this message, please notify the sender immediately, and delete the message and any attachments. Any disclosure, reproduction, distribution or other use of this message or any attachments by an individual or entity other than the intended recipient is prohibited.
